You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
"Extra Innings”: Using Serious Gaming and the Science of Baseball to Teach Science and Mathematics
SBC: DFUSION INC. Topic: 999DESCRIPTION provided by applicant Due to the rapid advances in science technology engineering and mathematics STEM the United States has been at the forefront of innovation and technology development in the science health and biomedical fields However these continuing advances are in jeopardy as there is a growing national shortage of trained STEM workers While the need for a STEM li ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mechanistic Studies of a Novel Small Molecule HIV Inhibitor
SBC: ADVANCED GENETIC SYSTEMS, INC. Topic: 100DESCRIPTION provided by applicant There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens The Rev RRE protein RNA interaction in HIV plays an essential role in the transport of viral mRNA from the nucleus to the cytoplasm where it can be translated or packaged Previously we identified the thienopyridine scaffold that inhibited HIV ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system
SBC: FasCure Therapeutics LLC Topic: NIAIDDESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Breath ammonia monitoring device for children with urea cycle disorders
SBC: Lumina Diagnostics, Inc. Topic: NICHDDESCRIPTION provided by applicant We propose to develop a non invasive device to enable children with urea cycle disorders and their parents guardians and physicians to actively manage the disorder at home and improve outcomes in the clinic Urea cycle disorders UCD are inborn errors of metabolism that impair oneandapos s ability to convert ammonia NH a neurotoxin into urea which is ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis
SBC: XFIBRA, LLC Topic: NHLBIDESCRIPTION provided by applicant Activation of lung myofibroblasts LMF is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably LMF clearance by apoptosis may prevent development of lung fibrosis and lung injury and possibly allow recovery from reversal of lung fibrosis There is full agreement among tissue fibrosis experts that inhibiting o ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia
SBC: MICROFLUIDIC INNOVATIONS, LLC Topic: 102DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of iCrystal System for Rapid Crystallization of Biological Macromolecules
SBC: JUXTOPIA LLC Topic: 100DESCRIPTION provided by applicant Biological macromolecules are the machinery of life and understanding their function helps scientists to develop new drug treatments that target specific human diseases In this regard crystallization is routinely employed for the understanding of the molecular structures and the interactions of proteins with other biological and non biological materials Desp ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications
SBC: ARIMA GENOMICS, INC. Topic: 172DESCRIPTION provided by applicant Phenomenal advances in DNA sequencing technologies have enabled systematic identification of genetic variants in human individuals and the recent FDA marketing authorization of the first next generation genome sequencer signals the arrival of a new era of pharmacogenomics and personalized medicine Nevertheless DNA sequencing alone fails to provide complete i ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Rapid Diagnostics for Mucormycosis
SBC: VITALEX BIOSCIENCES LLC Topic: NIAIDDESCRIPTION provided by applicant Mucormycosis most commonly caused by Rhizopus oryzae is a life threatening infection that occurs in patients immunocompromised by diabetic ketoacidosis DKA neutropenia corticosteroid use and or increased serum iron Because of the rising prevalence of these risk factors the incidence of mucormycosis has risen Despite disfiguring surgery and aggressive ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
improving Cas9 mediated homologous recombination in pluripotent stem cells
SBC: APPLIED STEMCELL, INC. Topic: 200DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health